Situaciones especiales: melanoma de mucosas, melanoma ocular y metástasis cerebrales > 117 15. Najjar YG, Navrazhim K, Ding F, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicentre, retrospective study. J Immunother Cancer 2020;8:e000331. 16. Pelster M, Gruschkus SK, Rasett R, et al. Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). J Clin Oncol 2019; 37(Suppl 15):9522. 17. Osella-Abate S, Ribero S, Sanlorenzo M, et al. Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. Int J Cancer 2015;136:2453. 18. Bedikian AY, Wei C, Detry M, et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 2011;34:603. 19. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 2016;17:976. 20. Long GV, Atkinson V, Lo S, Sandhu S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018;19(5):672-81. DOI: 10.1016/S1470-2045(18)30139-6. Epub2018 Mar 27. 21. McArthur GA, Maio M, Arance A, et al. Vemurafenib in Metastatic Melanoma Patients with Brain Metastases: An Open-Label, Single-Arm, Phase 2, Multicentre Study. Ann Oncol 2017;1;38(3):634-41. 22. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087. 23. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18(7):863-73.
RkJQdWJsaXNoZXIy OTI4NTYw